Correction to: Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013 (World Psychiatry, (2017), 16, 2, (181-192), 10.1002/wps.20421);Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013

World Psychiatry

Volumn 16, Issue 2, 2017, Pages 181-192

  Khan, Arif ^a,b   Fahl Mar, Kaysee ^a   Faucett, Jim ^a   Khan Schilling, Shirin ^a,c   Brown, Walter A ^d  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

antidepressant placebo difference; Antidepressants; clinical trials; effect size; enhanced interview techniques; placebo response; success rate

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SERTRALINE; TRAZODONE; VENLAFAXINE; VILAZODONE; VORTIOXETINE;

ARTICLE; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; EXPLORATORY FACTOR ANALYSIS; FOOD AND DRUG ADMINISTRATION; HAMILTON DEPRESSION RATING SCALE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

EID: 85019224711     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20469     Document Type: Erratum

References (44)

1. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Arch Gen Psychiatry 2000;57:311-7.
2. Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 2002;5:193-7.
3. Walsh BT, Seidman SN, Sysko R et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2001;287:1840-7.
4. Khan A, Detke M, Khan S et al. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 2003;191:211-8.
5. Rief W, Nestoriuc Y, Weiss S et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009;118:1-8.
6. Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012;37:851-64.
7. Weimer K, Colloca L, Enck P. Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry 2015;2:246-57.
8. Mancini M, Wade AG, Perugi G et al. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants. J Psychiatr Res 2014;51:21-9.
9. Khin NA, Chen Y, Yang Y et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of New Drug Applications. J Clin Psychiatry 2011;72:464-72.
10. Furukawa TA, Cipriani A, Atkinson LZ et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomized controlled studies. Lancet Psychiatry 2016;3:1059-66.
11. Enck P. Placebo response in depression: is it rising? Lancet Psychiatry 2016;3:1005-6.
12. Khan A, Kolts RL, Thase ME et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004;161:2045-9.
13. Papakostas GI, Ostergaard SD, Iovieno N. The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry 2015;76:456-66.
14. Khan A, Leventhal RM, Khan SR et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002;22:40-5.
15. Khan A, Brodhead AE, Kolts RL et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005;29:145-50.
16. Khan A, Schwartz K, Kolts RL et al. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiatry 2007;62:65-71.
17. Khan A, Khan SR, Walens G et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration Summary Basis of Approval reports. Neuropsychopharmacology 2003;28:552-7.
18. Khan A, Khan SR, Leventhal RM et al. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database. Int J Neuropsychopharmacol 2001;4:113-8.
19. Demitrack MA, Faries D, Herrera JM et al. The problem of measurement error in multisite clinical trials. Psychopharmacol Bull 1998;34:19-24.
20. Kobak K, Thase ME. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 2007;27:1-5.
21. Kobak KA, Feiger AD, Lipsitz JD. Interview quality and signal detection in clinical trials. Am J Psychiatry 2005;162:628.
22. Khan A, Faucett J, Brown WA. Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped, and appraised rater interviews compared to traditional rating interviews. J Psychiatr Res 2014;51:88-92.
23. Khan A, Faucett J, Brown WA. Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interview (SIGMA-RAPS) compared to trials using traditional semi-structured interviews. Psychopharmacology 2014;231:4301-7.
24. Stein DJ, Baldwin DS, Dolberg OT et al. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006;67:1741-6.
25. Kirsch K, Deacon BJ, Huedo-Medina TB et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45.
26. Fournier JC, DeRubeis RJ, Hollon SD. Antidepressant drug effects depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.
27. Naudet F, Millet B, Charlier P et al. Which placebo to cure depression? A thought-provoking network meta-analysis. BMC Med 2013;11:230.
28. Moncrieff J. Antidepressants: misnamed and misrepresented. World Psychiatry 2015;14:302-3.
29. Fountoulakis KN, Möller H. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 2011;14:405-12.
30. Cipriani A, Geddes JR. Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism. BMC Med 2014;12:105.
31. Montgomery SA. Antidepressant or antidepressant plus placebo effect? World Psychiatry 2015;14:303-4.
32. Kasper S, Dold M. Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry 2015;14:304-6.
33. Khan A, Brown WA. Antidepressants vs. placebo in major depression: an overview. World Psychiatry 2015;14:294-300.
34. Moore TJ, Mattison DR. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med 2017;177:274-5.
35. Sinyor M, Levitt AJ, Cheung AH et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analysis. J Clin Psychiatry 2010;71:270-9.
36. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009;19:34-40.
37. Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013;170:723-33.
38. Food and Drug Administration. www.accessdata.fda.gov.
39. Turner EH, Matthews AM, Linardatos E et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
40. Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med 2008;5:1348-56.
41. Gibertini M, Nations K, Whitaker J. Obtained effect size as function of sample size in approved antidepressants: a real-world illustration in support of better trial design. Int Clin Psychopharmacol 2012;27:100-6.
42. Turner EH, Matthews AM, Linardatos E et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
43. Mahableshwarkar A, Jacobsen P, Serenko M et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry 2015;76:583-91.
44. Liu KS, Snavely DB, Ball WA et al. Is bigger better for depression trials? J Psychiatr Res 2008;42:622-30.